Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



New Product Launches Set to Unleash Multiple Growth Avenues in U.S. Monoclonal Antibodies Market - The U.S. therapeutic monoclonal antibodies market is poised for a quantum leap with the launch of a multitude of new products and vigorous expansion of therapeutic indications of existing products
New Product Launches Set to Unleash Multiple Growth Avenues in U.S. Monoclonal Antibodies Market

 

PRZOOM - /newswire/ - Palo Alto, CA, United States, 2008/06/09 - The U.S. therapeutic monoclonal antibodies market is poised for a quantum leap with the launch of a multitude of new products and vigorous expansion of therapeutic indications of existing products.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A combination of these factors, along with high demand and lack of generic competition, expects to create exciting new possibilities and ensure continued market growth.

New analysis from Frost & Sullivan (pharma.frost.com), U.S. Biotechnology - Therapeutic Monoclonal Antibodies Market, finds the market earned revenues of over $12.61 billion in 2007 and estimates this to reach $34.47 billion in 2014.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the U.S. Monoclonal Antibodies Market, send an email to Johanna Haynes, Corporate Communications, at jhaynes_pr[.]frost.com, with the following information: your full name, company name, title, company telephone number, company email address, city, state, and country. We will send you the information via email upon receipt of the above information. All media inquiries please reply directly to johanna.haynes[.]frost.com.

“Several more marketed monoclonal antibodies are being approved for multiple indications, which increases the potential patient pool that can use these products,” says Frost & Sullivan Research Analyst Katheryn Symank. “This trend is also noted within the pipeline, where antibodies in development are being researched for several indications to maximize the possibility of receiving FDA approval.”

Accelerated approvals energize the marketplace. For instance, one of the new products has received FDA approval for seven different applications, while another is evaluated in Phase III clinical trials for the treatment of nine different diseases. Expansion of product lines, bolstered by additional indications, enables the use of this therapy by a wide cross-section of the patient populace.

In 2007, there were more than 20 active competitors in the market with new participants often making entry; meanwhile, competition continues to increase in this emerging market. Furthermore, over 50 companies are involved in developing new therapeutic monoclonal antibodies.

Research focused on vital improvements in monoclonal antibodies, such as refining its functions, along with expediting safety and efficacy. The launch of six new products – Erbitux, Avastin, Tysabri, Lucentis, Vectibix and Soliris, together with additional indications, expanded market potential to reach an extensive customer base. The fully human monoclonal antibody is the current weapon in the armory, although its development is limited by its complexity and high cost.

“As the inadequacies of conventional medicine were particularly apparent with regard to oncology, autoimmune and inflammatory disorders, monoclonal antibodies have offered a new approach, presenting a less toxic and more targeted solution,” notes Symank.

An emerging trend is the development of monoclonal antibodies used in conjunction with some vaccines. The outcome sees monoclonal antibodies boosting the immune system and triggering an effective response of the vaccine, a technique that is still undergoing clinical trials.

Despite proven effectiveness of therapeutic monoclonal antibodies, however, its high cost proves to be a deterrent to use. Therefore, it is imperative to demonstrate the capabilities of this therapy. In addition, companies must be more commercially astute to balance the cost constraints. Shining light on the benefits of therapeutic monoclonal antibodies against conventional therapies is one way to deal with the problem.

Furthermore, technological innovations make the production of monoclonal antibodies more efficient, which allows for greater yields and helps decrease cost. Extensive research can expedite the development of more targeted treatment options for various other diseases, and these advances encourage market expansion.

“Intensive research in genetic engineering, the immune system, and molecular biology has imbued the sector with a fresh impetus,” notes Symank. “Innovations, such as the use of monoclonal antibody fragments, rather than the full-length antibody, and the introduction of high-potency monoclonal antibodies are helping the momentum.”

U.S. Biotechnology - Therapeutic Monoclonal Antibodies Market is part of the Pharmaceutical and Clinical Diagnostics Growth Partnership Service program, which also includes research in the following markets: U.S. Smoking Cessation Markets, U.S. Asthma/COPD Market, and the U.S. Alcohol Dependence and Abuse Pharmaceuticals Market – Therapeutic Overview and Patient Outlook. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

U.S. Biotechnology - Therapeutic Monoclonal Antibodies Market
N167

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Product Launches Set to Unleash Multiple Growth Avenues in U.S. Monoclonal Antibodies Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Johanna Haynes 
210.247.3870 johanna.haynes[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today